



Plenary Session Materials and CLE Information

Plenary Session Supporting Materials

Plenary Session One: Life Sciences Dealmaking in 2025

- [Client Alert: FTC and DOJ Announce Final Rule Reshaping HSR Filing Requirements](#)
- [Client Alert: Revised Hart-Scott-Rodino Rules & Requirements Are Now in Effect](#)
- [Client Alert: Biden-Era M&A Data Shows Continuity, Not Revolution](#)
- [Media Mention: Healthcare and Life Science Deals Attys Expect In 2025](#)

Plenary Session Two: So You've Got Yourself a Promising Candidate – Planning Ahead for Commercialization

- [OIG's 2023 General Compliance Program Guidance](#)
- [OIG's 2003 Pharmaceutical Compliance Program Guidance](#)
- [FDA Draft Guidance on Accelerated Approval](#)
- [The Hatch-Waxman Act: A Primer](#)
- ["Skinny Labels" for Generic Drugs Under Hatch-Waxman](#)

Plenary Session Three: As AI Collides with The Drug Life Cycle, What Changes and What Doesn't?

- [Client Alert: FDA Releases Highly Anticipated Draft Guidance Documents on Artificial Intelligence Regarding Devices, Drugs, and Biological Products](#)
- [Blog Post: State Legislatures Consider New Wave of 2025 AI Legislation](#)
- [Blog Post: OECD Launches Voluntary Reporting Framework on AI Risk Management Practices](#)

CLE Credit

This program is approved for CLE in California and New York for both newly admitted and experienced attorneys.